Show 10 5 10 15 20 50 100 250 Sort by year (new to old) Actions News feed Embed this list Save this search Mark all Export Your filters: cql: parent exact "World journal of nuclear medicine" Mark conference C1 Synthesis, radiosynthesis and preliminary in vivo evaluation of [123I]-(1-(5-iodo-2-methoxyphenethyl)piperidin-4-yl)(4-fluorophenyl)methanone as a potential SPECT tracer for visualizing the 5-HT2A-receptor PETER BLANCKAERT (UGent) , Ingrid Burvenich and Guido Slegers (UGent) (2004) World journal of nuclear medicine. 3(3). p.236-237 Mark conference C1 123I-labelled monoclonal antibody 14C5 for SPECT tumour imaging: In vivo evaluation of athymic mice bearing a LoVo tumour Ingrid Burvenich, Bart Cornelissen, PETER BLANCKAERT (UGent) , Elisabeth Coene (UGent) , Claude Cuvelier (UGent) , Guido Slegers (UGent) , Steve Schoonooghe (UGent) and Nico Mertens (UGent) (2004) World journal of nuclear medicine. 3(3). p.243-244 Mark conference C1 Biological activity determination of I-BSP, a potent MMP 2 inhibitor, and its 123I tracer synthesis, World Journal of Nuclear Medicine, 2002, volume 1, supplement 2, S188 Ruth Oltenfreiter (UGent) , Ludovicus Staelens, A LEJEUNE, F FRANKENNE, Rudi Dierckx (UGent) and Guido Slegers (UGent) (2002) World Journal of Nuclear Medicine. 1(Suppl. 2). Mark conference C1 Synthesis and in vivo evaluation of [123I]-4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide, a potential sigma receptor ligand for SPECT studies Ludovicus Staelens, Filip Dumont, Filip De Vos (UGent) , Ruth Oltenfreiter (UGent) , Ingeborg Goethals (UGent) , Rudi Dierckx (UGent) and Guido Slegers (UGent) (2002) World Journal of Nuclear Medicine. 1(Supplement 2).